Zong Liju, Yang Junjun, Wang Xiaoyu, Kong Yujia, Ren Tong, Zhao Jun, Feng Fengzhi, Wan Xirun, Xiang Yang
Departments of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Cancer Manag Res. 2018 Mar 23;10:557-563. doi: 10.2147/CMAR.S160606. eCollection 2018.
The aims of this study were to analyze the clinical features, identify prognostic factors, and evaluate the survival outcomes of gestational trophoblastic neoplasia (GTN) patients with liver metastases.
Forty patients with liver metastases arising from GTNs, who were treated at the Peking Union Medical College Hospital (Beijing, People's Republic of China) between January 1999 and December 2015, were recruited from the institutional database, and their medical records were reviewed. Univariate and multivariate analyses were performed to identify independent risk factors for survival.
Twenty-seven patients (67.5%) achieved complete remission after multidrug chemotherapy treatment. The remaining 13 patients (32.5%) had disease progression. Eighteen patients (45.0%) died during treatment or follow-up. A history of failed multidrug chemotherapy was an independent risk factor for survival (OR: 5.57, 95% CI: 1.42-21.86, =0.014). Moreover, patients with an International Federation of Gynecology and Obstetrics (FIGO) score of >16 had a significantly poorer survival than those with a score of ≤16 (<0.001).
GTN with liver metastasis is a very rare disease with a relatively poor prognosis. Patients with a history of failed multidrug chemotherapy and a FIGO score of >16 have poorer survival outcomes. Multidrug chemotherapy is the key to the management of GTN patients with liver metastases.
本研究旨在分析妊娠滋养细胞肿瘤(GTN)肝转移患者的临床特征,确定预后因素,并评估其生存结局。
从机构数据库中纳入1999年1月至2015年12月在北京协和医院接受治疗的40例因GTN发生肝转移的患者,并对其病历进行回顾。进行单因素和多因素分析以确定生存的独立危险因素。
27例患者(67.5%)在多药化疗后达到完全缓解。其余13例患者(32.5%)疾病进展。18例患者(45.0%)在治疗或随访期间死亡。多药化疗失败史是生存的独立危险因素(OR:5.57,95%CI:1.42-21.86,P=0.014)。此外,国际妇产科联盟(FIGO)评分>16分的患者生存率明显低于评分≤16分的患者(P<0.001)。
GTN肝转移是一种非常罕见的疾病,预后相对较差。多药化疗失败史且FIGO评分>16分的患者生存结局较差。多药化疗是GTN肝转移患者管理的关键。